US-based pharmaceutical firm Continuus Pharmaceuticals has awarded a contract to construction firm Skanska to construct a new pharmaceutical manufacturing facility in Woburn, Massachusetts, US.
The contract, worth $125m, will be included in the company’s US order bookings for the fourth quarter of this year.
Go deeper with GlobalData
The scope of work under the contract involves renovation and construction of a new 50,000ft2 cGMP manufacturing facility in an existing shell space.
Dry active pharmaceutical ingredients (API) as well as finished drug products (DP) will be produced at the new facility in both tablet and sterile injectable forms.
The new pharmaceutical manufacturing plant will produce three critical care medicines as well as one additional key drug along with flexibility for future growth.
The company’s work under the contract also includes construction of a new third-floor penthouse, utility structure and extensive supporting utility equipment.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataA new dunnage system will be installed over the existing roof to support a modular air handling unit penthouse.
Skanska stated that the existing roof will be raised to enable additional equipment support areas and API manufacturing heights.
Construction work on the project is scheduled to be completed in the second quarter of next year.
Recently, the construction company announced €22m investment in a residential development project in Helsinki, Finland.
Located in the new area of Kruunuvuori, the development comprises 61 apartments.
Solar panels will be installed on the roof of the development to generate electricity, which will be used by the property.
Construction work of the project is anticipated to be completed in the fourth quarter of 2023.
———————————————————————————————————————
The new pharmaceutical manufacturing plant will produce three critical care medicines and one additional key drug. Credit: Arek Socha from Pixabay.
